Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MONET: PF-04523655 vs ranibizumab in neovascular AMD
2008-003210-10Phase 2Completed
- Sponsor
- Pfizer
- Start
- Sep 2008
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in age-related macular degeneration (AMD) and Subretinal neovascularization comparing PF-04523655 with Ranibizumab (Lucentis) (2 arms). Primary endpoint: Mean change from baseline in best corrected visual acuity at week 16. Started Sep 2008; status: completed.
02
Drugs
PF-04523655ranibizumab
03
Conditions
age-related macular degeneration (AMD)Subretinal neovascularization
Beyond the preview
Go deeper on 2008-003210-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003210-10.